Patients taking certolizumab pegol are twice as likely to achieve ACR20...
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to...
View ArticlePatients with PsA treated with ustekinumab are twice as likely to achieve...
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab...
View ArticleNew therapy extends life for prostate cancer patients
Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say...
View ArticleMany psoriasis patients undertreated for CV risk factors
(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the...
View ArticleMerck KGaA suffers setback on cancer drug
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.
View ArticleDrug fails to curb heart bypass complications, but surgery gets safer
A drug designed to shield the heart from injury during bypass surgery failed to reduce deaths, strokes and other serious events among patients at high risk of complications, according to a large,...
View ArticleRejected Alzheimer's drug shows new potential
An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's...
View ArticleStudy shows efficacy of new rheumatoid arthritis drug
(Medical Xpress) -- A new study involving researchers from Karolinska Institutet demonstrates the efficacy of Tofacitinib, a new drug for rheumatoid arthritis. According to the study, which is...
View ArticleRejected drug may protect against toxic substance common to Alzheimer's and...
The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep...
View ArticleDenosumab superior to zoledronic acid for breast cancer patients with bone...
Treatment with denosumab resulted in a greater reduction in skeletal-related events in patients with breast cancer that spread to the bones compared with zoledronic acid, while also maintaining...
View ArticleGolden age of prostate cancer treatment hailed as fourth drug in two years...
The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug...
View ArticleEnzalutamide adds five months survival in late-stage prostate cancer
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced...
View ArticlePrasugrel versus clopidogrel for ACS patients managed without revascularisation
The first trial to study the effect of platelet inhibition in patients with acute coronary syndromes managed medically without revascularisation has found no significant difference between prasugrel...
View ArticleMerck KGaA suffers setback for cancer drug
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
View ArticleL-carnitine does not reduce cancer-related fatigue
(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the...
View ArticleNovel therapy helps ease pain and suffering for sickle cell patients
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at...
View ArticleStudies show advances in gastrointestinal cancer treatments
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
View ArticlePhase III trial shows crizotinib superior to single-agent chemotherapy for...
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers...
View ArticlePhase III data in treatment of renal cell carcinoma reported
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in...
View ArticleCannabis extract eases muscle stiffness typical of multiple sclerosis
Cannabis seems to ease the painful muscle stiffness typical of multiple sclerosis, indicate phase III trial results, published in the Journal of Neurology Neurosurgery and Psychiatry.
View Article
